Documentos de Académico
Documentos de Profesional
Documentos de Cultura
DE
ESPECTRO
EXTENDIDO.
UN
PROBLEMA
ACTUAL.
Dr. Moiss Morejn Garca *
Desde el descubrimiento en 1940 de las penicilinasas, realizado por
dos
de
dichas
enzimas,
que
posteriormente
fueron
llamadas
Clase
Caracteristicas
molecular
1
solo
carbapenemicos,
resistentes
ac
clavulanico
2
A, D
Penicilinasas, Cefalosporinasas,
inhibidas por ac. clavulanico
2a
2b
2be
2br
B lactamasas IRT
Resistente a inhibidores de betalactamasas, excepto
tazobactam
2c
2d
2e
2f
3a, 3b, 3c
de
cepas
fundamentalmente
proveniente
a
pacientes
de
sepsis
comunitaria
inmunocomprometidos;
afectando
quemados,
18,19
el tracto
BIBLIOGRAFIA
1. Abraham,
EP,
Chain,
E.
An
enzyme
from
bacteria
able
15. Fierer J. & Guiney D.: Extended -Spectrum B-Lactamases "A plague
of plasmids". JAMA. 1999;281: 563,
16. Babini GS, Livermore DM. Antimicrobial resistance among Klebsiella
spp. collected from intensive care units in Southern and Western
Europe in 1997. J. Antimicrobial Chemother 2000;45:183.189
17. Paterson DL. Extended-spectrum beta-lactamases: the European
experience. Curr Opin Infect Dis 2001;14:697-701
18. Bermejo J, Lesnaberes P, Arnesi N y cols. Factores de riesgo
asociados con las infecciones debidas a Klebsiella pneumoniae
resistentes a ceftazidima. Enferm Infecc Microbiol Clin 2003;21:69-71
19. Gobernado M. Betalactamasas de espectro extendido en aumento.
Rev Esp Quimioterap 2005;18(2):115-117
20. Asensio A, Oliver A, Gonzalez-Diego P, y cols. Outbreak of a
multiresistant Klebsiella pneumoniae strain in an intensive care unit:
Antibiotic use as risk factor for colonization and infection. Clin Infect
Dis 2000;30:55-60
21. Gniadkouwski M. Evolution and epidemiology of extended espectrum
betalactamases (ESBLs) and ESBL- producing microorganisms. Clin
Microbiol Infect 2001;7:597-608
22. Jones RN, Pfaller MA, Doern GV, Erwin ME, Hollis RJ. Antimicrobial
activity and spectrum investigation of eight broad-spectrum betalactam drugs: a 1997 surveillance trial in 102 medical centers in the
United States. Cefepime Study Group. Diagn Microbiol Infect Dis
1998; 30: 215-228.
23. Biedenbach DJ, Johnson DM, Jones RN. In vitro evaluation of
cefepime and other broad-spectrum beta-lactams in eight medical
centers in Thailand. The Thailand Antimicrobial Resistance Study
Group. Diagn Microbiol Infect Dis 1999; 35: 325-331.
24. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and
spectrum of selected extended-spectrum beta-lactams (carbapenems
and cefepime) against Enterobacter spp. and ESBL-producing
Klebsiella spp.: report from the SENTRY antimicrobial surveillance
program (USA, 1997-2000). Int J Antimicrob Agents 2003; 21: 1-7.
25. Johnson DM, Biedenbach DJ, Jones RN. Potency and antimicrobial
spectrum update for piperacillin/tazobactam (2000): emphasis on its
activity against resistant organism populations and generally untested
species causing community-acquired respiratory tract infections.
Diagn Microbiol Infect Dis 2002; 43: 49-60.
26. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the
inoculum effect in tests with extended-spectrum beta-lactamaseproducing Enterobacteriaceae. Antimicrob Agents Chemother 2001;
45: 3548-3554.
27. Ambrose
PG,
Bhavnani
SM,
Jones
RN.
Pharmacokinetics-